Business Context and Reporting Period
This Form 8-K, dated July 8, 2025, reports on events occurring on July 7, 2025, for Silexion Therapeutics Corp, a Cayman Islands exempted company. The filing addresses the outcome of a Nasdaq hearings panel regarding the Company's listing status following a delisting notice received on May 22, 2025.
Key Financial Metrics and Listing Status
The filing does not provide specific revenue, profit, cash flow, or debt figures. The primary financial metric disclosed relates to listing compliance:
- Shareholders' Equity Requirement: The Company must achieve at least $2.5 million in shareholders' equity to comply with the Nasdaq Capital Market Equity Standard.
- Listing Transfer: Securities are expected to transfer from the Nasdaq Global Market to the Nasdaq Capital Market on July 8, 2025, under symbols "SLXN" and "SLXNW".
Material Changes and Compliance Plan
The Nasdaq hearings panel granted a favorable decision allowing continued listing subject to a compliance plan. Key terms include:
- Equity Restoration Deadline: The Company must demonstrate compliance with the $2.5 million shareholders' equity requirement in a report filed on or before September 19, 2025.
- Minimum Bid Price Deficiency: The Company disclosed a potential deficiency under Nasdaq Listing Rule 5550(a)(2) due to a bid price below $1.00 for 30 consecutive trading days.
- Reverse Share Split: To remedy the bid price deficiency, the Company plans a 1-for-15 reverse share split, expected to be effected on or about July 25, 2025, pending shareholder approval at a reconvened annual general meeting on July 14, 2025.
- Extended Jurisdiction: If the Company fails to maintain compliance by November 18, 2025, it must submit a new compliance plan for review.
- Equity Risk: There is no assurance the Company will successfully raise the required $2.5 million in shareholders' equity by the September 19, 2025 deadline.
- Shareholder Approval Risk: The reverse share split is contingent on shareholder approval at the July 14, 2025 meeting; failure to approve could result in delisting due to the minimum bid price deficiency.
- Ongoing Compliance: Even if initial compliance is restored, there is no guarantee the Company can maintain the Equity Standard or other Nasdaq listing rules on an ongoing basis.
- Verify the outcome of the reconvened annual general meeting on July 14, 2025, specifically regarding the approval of the 1-for-15 reverse share split.
- Monitor the Company's filings to confirm the restoration of $2.5 million in shareholders' equity by the September 19, 2025 deadline.
- Track the trading price of ordinary shares to ensure the reverse share split successfully cures the minimum bid price deficiency by late July 2025.
- Review the Company's Form 10-K for the year ended December 31, 2024, for detailed risk factors regarding capital raising and operational challenges.
Outlook, Risks, and Contingencies
Management provided forward-looking statements with significant caveats regarding the Company's ability to maintain listing status: